Sex hormones and possibly prolactin may play an important role in the control of neoplastic growth of breast cancer, but results of hormonal determination have often been contradictory. Most of the studies have found no significant increase in the circulating levels of oestrogens and prolactin (Nagasawa, 1979; Nisker & Siiteri, 1981; Zumoff, 1981) in breast cancer patients, and the few reports of testosterone levels are conflicting, normal values having been found by some authors (Bird et al., 1981; Borkowski et al., 1977; Horn & Gordan, 1974) and increased levels by others (Adami et al., 1979; McFadyen et al., 1976) . Malarkey et al. (1977) reported increased testosterone levels in premenopausal and normal testosterone levels in postmenopausal patients.
In the present work we report circulating levels of testosterone, oestradiol, prolactin, and luteinising hormone (LH) in postmenopausal breast cancer patients and in normal controls. The finding of increased testosterone levels in breast cancer patients supports our previous findings based on urine measurements (Grattarola et al., 1974 (Grattarola et al., , 1975 0007-0920/83/020269-07 $02.00 undergone mastectomy for infiltrating carcinoma of the breast were studied. All of them were diseasefree at the time of hormonal examination. The age of these patients was 47-77 y (mean 58.5 y) and all had been postmenopausal for 1-28 y. The patients were divided into 3 subgroups according to years since menopause: 10 patients were 1-5 y postmenopausal, 8 were 6-10 y postmenopausal, and 10 were >10 y postmenopausal.
Twenty-five of the 28 patients married between the age of 21 and 36 years and had had at least one full-term pregnancy between the ages of 23 and 41 years. Three patients were single and had had no pregnancy.
The patients were divided into 2 subgroups according to the interval between mastectomy and hormonal examination: 19 patients were examined from 2-12mo since mastectomy and 9 patients were examined from 2-17 y since mastectomy.
No patient had been previously ovariectomized and none had been treated with hormones or chemotherapy for breast cancer. None of them had been taking any hormonal drug for at least 6 mo before testing or digitalis, antihypertensive or psychotropic drugs for chronic disease.
Control subjects Thirty normal controls selected from healthy women fulfilled the following criteria: (a) no abnormality of the breast on clinical examination; (b) no benign or malignant neoplasm elsewhere; (c) no endocrine, metabolic or chronic disease; (d) no family history of breast cancer; (e) no involuntary infertility; (f) no menstrual cycle irregularities in the past.
Ages were 49-77 y (mean 57.4 y), and all had been postmenopausal for 1-30y. They were divided into 3 subgroups according to years since menopause: 12 were 1-5y postmenopausal, 11 were 6-10y postmenopausal, and 7 were >10 y postmenopausal.
Twenty-four had married between the ages of 18 and 30 y and delivered at least one full-term newborn between the ages of 20 and 32 y. Six control subjects were single and had had no pregnancy. Table I reports the ranges and means for the various characteristics of the patients and the controls.
Methods
Hormonal determinations were performed on peripheral blood samples drawn between 9 a.m. and 11 a.m. Blood was allowed to clot at room temperature, centrifuged and serum separated and stored at -20°C until assayed. Testosterone, oestradiol, LH and prolactin levels were determined by radioimmunoassay in the same blood samples.
For the determination of testosterone, preliminary chromatography was performed with a Sephadex LH-20 column according to the method of Collins et al. (1972) . However, since we wished to eliminate dihydrotestosterone we performed the assay of testosterone only on the fraction of elution between 0.9 and 2.0 ml immediately after the azobenzene.
The cross-reaction of the antibody towards testosterone-3-oximebovine serum albumin, which we used, was <0.1 % for all the principal steroids, except for dihydrotestosterone (17,B-hydroxy-5c-androstan-2-one), 5-androsten-313-177f-diol, and 5a-androstan-3a-17#-diol. These steroids were thus eliminated by chromatography.
The separation of free testosterone from that bound to the antibody was performed by use of the double antibody method (Ismail et al., 1972) . The levels of testosterone found'by interpolation of the standard curve were corrected for the recoveries (which were from 50-70%), whereas no correction was made for the blanks, since these were negligible.
The levels of oestradiol were determined without preliminary chromatography (Ricci & Sacconi, 1976) , using a rabbit antibody raised against 17#-oestradiol-6-carboxymethyloxime-bovine serum albumin, which was highly specific (Ricci & Sacconi, 1976) , and polyethylene glycol for separating bound from free steroid (Desbuquois & Aurbach, 1971) . LH and prolactin were respectively determined with the methods of Midgley (1966) and Sinha et al. (1973 (Greenwood et al., 1963), 2,4,6,7- [3H]-17f1-oestradiol, and the respective antibodies were supplied by Biodata (Milan, Italy).
The coefficients of intra-and inter-assay variation were respectively 9.5% and 18.3% for testosterone, 8% and 15% for oestradiol, 5.5% and 7% for LH, and 5.86% and 9% for prolactin. Comparisons of hormone levels between cancer and control groups and between their subgroups "time since mastectomy" and "years since menopause" were performed by Student's t-test, after conversion of data to a logarithmic scale. The correlation between the 4 hormones studied in the control group and in the cancer group and the correlation of each hormone with age at menopause and years since menopause were analyzed by determining the linear coefficient of correlation with the corresponding P values. Two-tailed P values were considered for all the statistical analyses.
Results
Mean age, mean age at menopause, mean time since menopause to hormonal examination, and mean age at marriage did not differ significantly between normal controls and breast cancer patients. Mean age at first pregnancy was signficiantly lower in the control group (P<0.01) and mean number of full-term pregnancies was significantly lower in the breast cancer group (P<0.02) ( Table I) . Within the breast cancer group, the subgroups 2-12mo since mastectomy and >2 y since mastectomy did not differ significantly for age, age at menopause and years since menopause.
Testosterone
The mean value in the breast cancer group was 0.554+0.2ngml-1 and in normal controls 0.318+0.llngml-1 (P<0.001) ( Table II) . The distribution was shifted to higher values in the patient group, where we found values exceeding 0.58 ng ml1 (upper limit for normal controls) in 14 patients.
Time since mastectomy The mean testosterone value in the 19 patients examined within 12 mo of mastectomy was higher than in 9 patients examined (Table IV) .
17,B-Oestradiol
The mean value in the breast cancer group did not differ significantly from that of the control group (Table II) .
Time since mastectomy No statistical difference was found in the mean oestradiol levels between 17 patients examined close to mastectomy and 7 patients examined years after surgery, or between each subgroup and the control group (Table III) .
Years since menopause No significant difference was found between normal controls and breast cancer patients in any of the 3 subgroups, and no significant difference was found between the 3 subgroups in the control group or in the breast cancer group (Table IV) .
Luteinising hormone (LH) There was a wide range of variation in both breast cancer patients and normal controls, and no significant difference between them (Table II) .
Time since mastectomy The mean value in the 9 patients examined years after mastectomy was higher than in the 19 patients examined 2-12mo after surgery, but the difference was not statistically significant (t = 2.0). No statistical difference was found between each subgroup and the control group (Table III) . (Table IV) .
Prolactin
The distribution was slightly but not significantly shifted to higher values in the patient group (Table  II) .
Time since mastectomy No difference was found in the mean prolactin levels between the 19 patients examined 2-12mo after mastectomy and the 9 patients examined years after surgery, or between each subgroup and the control group (Table III) . Years since menopause A statistically significant difference was found between controls and patients in late postmenopause (> IOy since menopause) (P <0.02) but not in the other subgroups. No significant difference was found between the 3 subgroups, either within the control group or within the breast cancer group (Table IV) . Correlations No correlation was found between the 4 hormones studied, either in the control group or in the breast cancer group, considering the overall groups or dividing them into subgroups according to years since menopause or, for the patient group, according to time since mastectomy. A statistically significant correlation was found between testosterone and years since menopause (r=0.533, P <0.01) in breast cancer patients but not in normal controls. Years since menopause were not correlated with oestradiol, LH or prolactin levels in either group. No correlation was found between any of the 4 hormones studied and age at menopause in the control group, the breast cancer group, or their subgroups.
Discussion
The present results show that mean values of serum oestradiol, LH and prolactin are similar in postmenopausal women with breast cancer and normal controls. These findings are in agreement with most data from the literature for oestradiol (Bird et al., 1981; Borkowski et al., 1977; England et al., 1977; Jones et al., 1977; Malarkey et al., 1977; McFadyen et al., 1976) , LH (Bird et al., 1981; Malarkey et al., 1977; McFadyen et al., 1977) and prolactin levels (Franks et al., 1974; Jones et al., 1977; Kwa et al., 1974; Mittra et al., 1974; Sheth et al., 1975) .
In our series, testosterone levels in breast cancer patients were significantly higher than in normal controls, considering either the overall groups or dividing them into subgroups according to years since menopause or, for the patient group, according to time since mastectomy.
These data confirm the findings of our previous papers (Grattarola et al., 1974 (Grattarola et al., , 1975 , in which urinary testosterone values higher than normal were found in postmenopausal breast cancer patients. Reports of blood testosterone levels in these patients are few and conflicting (Adami et al., 1979; Bird et al., 1981; Borkowski et al., 1977; Horn & Gordan, 1974; Malarkey et al., 1977; McFadyen et al., 1976) . In his review of plasma hormone concentration in human breast cancer, Zumoff (1978) pointed out that "in most studies the groups were heterogeneous, complicated by other diseases and/or medications, and poorly or not at all characterized." Our patients were rigidly selected according to predetermined criteria. In the control group, testosterone values were in agreement with E normal values in most other reports (Adami et al., 1979; Bird et al., 1981; Malarkey et al., 1977; Vermeulen, 1976) .
Our data have been obtained on the basis of a single "spot" sample, which has been criticized (Zumoff, 1978) . Diurnal variations of testosterone in postmenopausal women were shown by Vermeulen (1976) , with highest levels at 8a.m. and a significant decrease at 8p.m., but the differences between 8a.m. and 12a.m. were very small. Time of sampling in our series, both for controls and breast cancer patients, was between 9 a.m. and 11 a.m. We feel it is unlikely that difference in sampling time can account for the highly significant difference in testosterone values between the control group and the breast cancer group, where 50% of the patients had testosterone levels higher than the highest testosterone value in the controls. Furthermore, the correlation of years since menopause with testosterone but not with the other hormones is highly suggestive of some abnormality just in testosterone production and metabolism rather than for some casual event.
Adipose tissue aromatizes androgens to oestrogens (Nimrod & Ryan, 1975) and body weight and the percentage of conversion of androstenedione to oestrone are highly correlated in women (Siiteri & MacDonald, 1973) . A highly significant correlation was found -between body weight and circulating oestrogens in normal postmenopausal subjects and in patients with endometrial adenocarcinoma Judd et al., 1980) , but no correlation was present between body weight and testosterone. Body weight was recorded in about half of our patients, and it did not differ from that of the controls.
There is evidence that postmenopausal ovaries continue to secrete significant amounts of androgenic hormones (Judd et al., 1974a, 1 974b; Schenker et al., 1979; Vermeulen, 1976) , whereas oestrogens after the menopause are derived almost completely from the peripheral conversion of androgens (Grodin et al., 1973) . Androgens are known to be synthesized in the interstitial tissue of the ovary (Rice & Savard, 1966) , and a high incidence of hyperplastic ovarian interstitial tissue has been described in breast cancer patients (Smith & Smith, 1953; Sommers, 1955; Sommers & Teloh, 1952) . A previous study from our laboratory (Grattarola, 1976) showed ovarian interstitial hyperplasia and elevated urinary testosterone excretion in a large number of pre-and postmenopausal breast cancer patients submitted to ovariectomy.
We can surmise that ovarian interstitial hyperplasia is more frequent in breast cancer patients than in normal controls and that the hyperplastic tissue, under stimulation of elevated gonadotropin levels, continues to produce larger and larger amounts of testosterone with the years since menopause. On the other hand, hormonal production in normal postmenopausal ovaries is steady or slightly decreased with years since menopause.
In conclusion, these data confirm our previous findings of increased urinary testosterone in breast cancer patients (Grattarola et al., 1974 (Grattarola et al., , 1975 , and further support the hypothesis that hyperandrogenism may play a role in the development of breast cancer.
Although our data cannot answer the question whether the abnormality in testosterone levels is simply a result of mastectomy itself or whether it was present preoperatively and indicates a true metabolic difference between those women destined to develop breast cancer and those who are not, we surmise that the latter hypothesis is more probable. In fact, increased urinary excretion of testosterone and androstanediol was reported (Grattarola, 1978) in patients with hyperplastic alterations of breast epithelium, which is a risk factor for breast cancer, and we recently found urinary testosterone and androstanediol excretion higher than normal in 39% of patients with hyperplasia and in 61% of patients with cancer of the breast, examined before mastectomy (Secreto et al., 1982) .
